A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules.
Latest Information Update: 23 Feb 2012
At a glance
- Drugs IDP 107 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Dow Pharmaceutical Sciences
- 29 Nov 2011 Status changed from not stated to completed.
- 29 Nov 2011 New trial record